Eckert & Ziegler Takes Measures to Significantly Increase U.S. Availability of GalliaPharm(R) Pharmaceutical Grade Germanium-68/Gallium-68 Generators
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Miscellaneous Berlin, Germany, 5 October 2018. Eckert & Ziegler Strahlen-und-Medizintechnik AG (EZAG), through its wholly owned subsidiary Eckert & Ziegler Radiopharma GmbH (EZR), recently submitted to the U.S. Food and Drug Administration (U.S. FDA) an amendment of its Drug Master File (DMF) for its pharmaceutical grade Germanium-68/Gallium-68 generator, GalliaPharm(R). If found acceptable, the amendment will allow nuclear pharmacists to achieve a significantly higher number of elutions per generator and thereby increase the average availability of Gallium-68 in U.S. hospitals by about 40%. Contact:
05.10.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | 49 30 941084-138 |
Fax: | 49 30 941084-112 |
E-mail: | karolin.riehle@ezag.de |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |